<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03414034</url>
  </required_header>
  <id_info>
    <org_study_id>TROV-053</org_study_id>
    <secondary_id>U1111-1208-1579</secondary_id>
    <nct_id>NCT03414034</nct_id>
  </id_info>
  <brief_title>Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <official_title>A Phase 2 Study of PCM-075 (Onvansertib) in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiff Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiff Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the phase 2 study is to determine whether Onvansertib is safe and tolerable in&#xD;
      adult participants with Metastatic Castration-Resistant Prostate Cancer who have disease&#xD;
      progression while receiving abiraterone acetate (abiraterone) and prednisone therapy, and to&#xD;
      observe the effects of Onvansertib in combination with abiraterone and prednisone on disease&#xD;
      control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2018</start_date>
  <completion_date type="Anticipated">May 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 13, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Lack of Prostate-specific Antigen (PSA) Progression per Prostate Cancer Working Group 3 (PCWG3) Criteria After 12 Weeks</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change from Baseline in PSA at 12 Weeks</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal Percentage Change from Baseline in PSA</measure>
    <time_frame>Baseline up to 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change from Baseline in PSA Response</measure>
    <time_frame>Baseline up to 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA Progression per PCWG3 criteria</measure>
    <time_frame>Baseline up to 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Radiographic Progression per PCWG3 criteria</measure>
    <time_frame>Baseline up to 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Response per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)</measure>
    <time_frame>Baseline up to 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who are Adherent to Study Treatment (Per-Protocol Analysis) With Lack of Prostate-specific Antigen (PSA) Progression per Prostate Cancer Working Group 3 (PCWG3) Criteria After 12 Weeks</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events per Common Terminology Criteria for Adverse Events (CTCAE)</measure>
    <time_frame>Baseline up to 30 days after last dose of study drug (Up to 20 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Up to 20 months</time_frame>
    <description>DLT is defined as a hematologic adverse event (AE) of Grade ≥ 3 or nonhematologic AE of Grade ≥ 3 considered related to the study drug(s).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Metastatic Castration-Resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: onvansertib + abiraterone and prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 24 mg/m^2 for 5 days (Day 1 through Day 5) out of a 21-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone. This arm was discontinued.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: onvansertib + abiraterone and prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 24 mg/m^2 for 5 days (Day 1 through Day 5) out of a 14-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: onvansertib + abiraterone and prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 12 mg/m^2 for 14 days (Day 1 through Day 14) out of a 21-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onvansertib</intervention_name>
    <description>Onvansertib orally</description>
    <arm_group_label>Arm A: onvansertib + abiraterone and prednisone</arm_group_label>
    <arm_group_label>Arm B: onvansertib + abiraterone and prednisone</arm_group_label>
    <arm_group_label>Arm C: onvansertib + abiraterone and prednisone</arm_group_label>
    <other_name>PCM-075</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>Abiraterone orally</description>
    <arm_group_label>Arm A: onvansertib + abiraterone and prednisone</arm_group_label>
    <arm_group_label>Arm B: onvansertib + abiraterone and prednisone</arm_group_label>
    <arm_group_label>Arm C: onvansertib + abiraterone and prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone orally</description>
    <arm_group_label>Arm A: onvansertib + abiraterone and prednisone</arm_group_label>
    <arm_group_label>Arm B: onvansertib + abiraterone and prednisone</arm_group_label>
    <arm_group_label>Arm C: onvansertib + abiraterone and prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males ≥ 18 years of age on the day of consenting to the study.&#xD;
&#xD;
          2. Ability to swallow the study drug as a whole tablet.&#xD;
&#xD;
          3. Histologically confirmed prostate adenocarcinoma without significant small-&#xD;
             cell/neuroendocrine or other variant histologies, with rising PSA and/or radiographic&#xD;
             progression in the setting of castration-level testosterone (&lt; 50 ng/dL) indicating&#xD;
             mCRPC. Participants must have either undergone surgical castration or continue on GnRH&#xD;
             agonist/antagonist on the appropriate schedule throughout the study period.&#xD;
&#xD;
          4. Asymptomatic or minimally symptomatic disease.&#xD;
&#xD;
          5. Metastatic disease by bone scan or other nodal or visceral lesions on CT or MRI at any&#xD;
             time (past or present).&#xD;
&#xD;
          6. Participant currently receiving abiraterone and prednisone for CRPC.&#xD;
&#xD;
          7. Participant has been on abiraterone for castration-sensitive prostate cancer (CSPC) or&#xD;
             castration-resistant prostate cancer (CRPC). Participants who have received&#xD;
             abiraterone for CSPC must have had a response to hormonal therapy, as defined by any&#xD;
             decline in PSA, radiographic response and/or clinical benefit after starting hormonal&#xD;
             therapy.&#xD;
&#xD;
             Participants who have received abiraterone for CRPC must have responded to&#xD;
             abiraterone, defined by any decline in PSA, radiographic response, and/or clinical&#xD;
             benefit after starting abiraterone.&#xD;
&#xD;
          8. Two rising PSA values separated by at least 1 week, one showing a rise of at least 0.3&#xD;
             ng/mL and one confirmatory value not showing a decline, while on abiraterone therapy.&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1&#xD;
&#xD;
         10. Participant has adequate bone marrow and organ function as shown by:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.0 x 109/L&#xD;
&#xD;
               -  Platelets ≥ 100 x 10^9/L&#xD;
&#xD;
               -  Hemoglobin (Hgb) ≥ 9.0 g/dL&#xD;
&#xD;
               -  Serum creatinine ≤ 2 x the upper limit of normal (ULN)&#xD;
&#xD;
               -  Total serum bilirubin ≤ 1.5 x ULN (in participants with known Gilbert Syndrome, a&#xD;
                  total bilirubin ≤ 3.0 x ULN, with direct bilirubin ≤ 1.5 x ULN)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN (or&#xD;
                  ≤ 5.0 x ULN if hepatic metastases are present)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Major surgery within 28 days prior to starting study drug or has not recovered from&#xD;
             major side effects of the surgery.&#xD;
&#xD;
          2. Rapidly progressive symptoms of mCRPC.&#xD;
&#xD;
          3. Acute neurological dysfunction as a result of bone metastasis.&#xD;
&#xD;
          4. Previously treated with enzalutamide or experimental therapies directed against&#xD;
             androgen receptor (ie, apalutamide).&#xD;
&#xD;
          5. Use of any chemotherapy, investigational agents, immunotherapy, or hormonal therapy&#xD;
             other than GnRH agonists within 28 days of the start of treatment on protocol.&#xD;
&#xD;
             Use of bone targeted agents including bisphosphonates and RANK ligand inhibitors is&#xD;
             allowed if on stable dose; Xgeva or Zometa cannot be started within 28 days of&#xD;
             initiating study therapy.&#xD;
&#xD;
          6. Systemic corticosteroids except as part of on label treatment prostate cancer&#xD;
             regimens. Note: Topical applications (eg, rash), inhaled sprays (eg, obstructive&#xD;
             airways diseases), eye drops or local injections (eg, intra-articular) are allowed.&#xD;
&#xD;
          7. Treatment with any of the drugs listed in Section 8.4.5 at the time of study treatment&#xD;
             initiation.&#xD;
&#xD;
          8. Has received wide field radiotherapy (including therapeutic radioisotopes such as&#xD;
             radium 223) ≤ 28 days or limited field radiation for palliation ≤ 14 days prior to&#xD;
             starting study drug or has not recovered from side effects of such therapy.&#xD;
&#xD;
          9. New York Heart Association (NYHA) Class III or IV heart disease, active ischemia or&#xD;
             any other uncontrolled cardiac condition, or hypertensive or metabolic condition.&#xD;
&#xD;
         10. Myocardial infarction in the previous 12 weeks (from the start of treatment)&#xD;
&#xD;
         11. QT interval with Fridericia's correction [QTcF] &gt;470 milliseconds. The QTcF should be&#xD;
             calculated as the arithmetic mean of the QTcF on triplicate ECGs. In the case of&#xD;
             potentially correctible causes of QT prolongation (e.g., medications, hypokalemia),&#xD;
             the triplicate ECG may be repeated once during screening and that result may be used&#xD;
             to determine eligibility.&#xD;
&#xD;
         12. Planned concomitant use of medications known to prolong the QT/QTc interval&#xD;
&#xD;
         13. Presence of risk factors for torsade de pointes, including family history of Long QT&#xD;
             Syndrome or uncorrected hypokalemia.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Central Contact Lead</last_name>
    <phone>858-952-7652</phone>
    <email>VKelemen@trovagene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-724-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-632-9281</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-632-6328</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 22, 2018</study_first_submitted>
  <study_first_submitted_qc>January 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PLK1</keyword>
  <keyword>PLK Inhibitor</keyword>
  <keyword>Onvansertib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Onvansertib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

